BOULDER, Colo., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Biodesix will conduct an oral presentation on immunotherapy biomarkers in addition to presenting data from two separate studies at the SITC 2017 Annual Meeting. All three presentations will focus on tests and methods developed via MALDI-ToF mass spectrometry and using the company’s proprietary machine learning platform, and will be made at in National Harbor, MD, at the Gaylord Hotel and Conference Center.

Oral Presentation: “Biomarkers for primary immunotherapy resistance based on the circulating proteome”
Speaker: Heinrich Roder, D.Phil
Date/Time: Wednesday, November 8, 9:40AM EST

Poster: “Proteomic biomarker analysis of metastatic melanoma patients treated with anti-PD-1 checkpoint blockade.”
Presenter: TBA.
Authors: PA Ascierto, M Capone, AM Grimaldi, D Mallardo, E Simeone, H Roder, K Meyer, S Asmellash, C Oliveira, J Roder
Date/Time: Friday, November 10, 12:30-2:00PM; 6:30-8:00PM EST.

Poster:  “Mass spectrometry-based test predicts outcome on anti-PD-1 therapy for patients with advanced non-small cell lung cancer, including those with brain metastases.”
Presenter: TBA.
Authors: Sarah B. Goldberg, Lucia Jilaveanu, Harriet M. Kluger,  Veronica Chiang, Amit Mahajan, Bing Xia, Matthew Ribeiro, Heinrich Roder,  Joanna Roder, Carlos Oliveira, Julia Grigorieva, Mirte Muller, Anna-Larissa Niemeijer,  Adrianus de Langen, Robert Schouten, Egbert Smit
Date/Time: Friday, November 10, 12:30-2:00PM; 6:30-8:00PM EST.

About Biodesix

Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests and with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.

For more information about Biodesix, please visit www.Biodesix.com.

CONTACT: Contact: Rachel Biederman
720-214-5774
rachel.biederman@biodesix.com

Ads